KLOW Stack Research Guide: GHK-Cu + TB-500 + BPC-157 + KPV
KLOW extends the classic GLOW stack with KPV, adding an α-MSH-derived anti-inflammatory arm to the copper/actin/VEGFR2 combination.
Component mechanisms
GHK-Cu — copper tripeptide for matrix remodeling and antioxidant enzyme activity.
TB-500 — thymosin β-4 fragment for actin sequestration and cell migration.
BPC-157 — pentadecapeptide for VEGFR2 and nitric-oxide-mediated tissue repair.
KPV — α-MSH tripeptide for NF-κB inhibition and cytokine reduction.
Sourcing & purity
Research-grade material should be ≥99% pure by HPLC with peptide content confirmed via mass spectrometry. Redline Bio material ships with batch documentation; independent third-party COAs are published on the lab reports page as testing returns.
Compliance reminder
Sold and distributed for laboratory research use only. Not approved by the FDA for human consumption, diagnosis, treatment, or cure of any disease. Researchers are responsible for compliance with all applicable institutional, state, and federal regulations.
Frequently asked questions
What is in KLOW?
Each 80 mg KLOW vial contains 50 mg GHK-Cu, 10 mg TB-500, 10 mg BPC-157, and 10 mg KPV.
Why add KPV to the GLOW formula?
KPV brings a distinct anti-inflammatory mechanism (NF-κB modulation via PepT1 transport) that complements the angiogenic and tissue-repair arms of BPC-157, TB-500, and GHK-Cu.